Xizang Haisco Pharmaceutical Group Co Ltd Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd asset resilience ratio. Xizang Haisco Pharmaceutical Group Co Ltd (002653) has an Asset Resilience Ratio of 1.69% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xizang Haisco Pharmaceutical Group Co Lt defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xizang Haisco Pharmaceutical Group Co Ltd (2008–2024)
Asset resilience ratio of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2024. This chart shows how Xizang Haisco Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Read debt load of Xizang Haisco Pharmaceutical Group Co Lt for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Xizang Haisco Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002653 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥133.00 Million | 1.69% |
| Total Liquid Assets | CN¥133.00 Million | 1.69% |
Asset Resilience Insights
- Limited Liquidity: Xizang Haisco Pharmaceutical Group Co Ltd maintains only 1.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xizang Haisco Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Xizang Haisco Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Xizang Haisco Pharmaceutical Group Co Ltd Asset Resilience Ratio by Year (2008–2024)
Xizang Haisco Pharmaceutical Group Co Ltd asset resilience ratio by year from 2008 to 2024. The table below shows the annual Asset Resilience Ratio data for Xizang Haisco Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.21% | CN¥150.13 Million ≈ $21.97 Million |
CN¥6.80 Billion ≈ $994.82 Million |
-0.20pp |
| 2023-12-31 | 2.41% | CN¥160.06 Million ≈ $23.42 Million |
CN¥6.65 Billion ≈ $973.53 Million |
+5.77pp |
| 2022-12-31 | -3.36% | CN¥-203.16 Million ≈ $-29.73 Million |
CN¥6.05 Billion ≈ $884.95 Million |
+0.30pp |
| 2021-12-31 | -3.66% | CN¥-183.34 Million ≈ $-26.83 Million |
CN¥5.01 Billion ≈ $732.43 Million |
-11.07pp |
| 2020-12-31 | 7.41% | CN¥370.32 Million ≈ $54.19 Million |
CN¥5.00 Billion ≈ $731.65 Million |
+0.84pp |
| 2019-12-31 | 6.56% | CN¥330.47 Million ≈ $48.36 Million |
CN¥5.04 Billion ≈ $736.82 Million |
-2.16pp |
| 2018-12-31 | 8.73% | CN¥380.99 Million ≈ $55.75 Million |
CN¥4.37 Billion ≈ $638.86 Million |
+6.90pp |
| 2017-12-31 | 1.83% | CN¥75.10 Million ≈ $10.99 Million |
CN¥4.11 Billion ≈ $601.25 Million |
+1.69pp |
| 2016-12-31 | 0.13% | CN¥5.00 Million ≈ $731.66K |
CN¥3.74 Billion ≈ $547.80 Million |
+0.24pp |
| 2015-12-31 | -0.11% | CN¥-3.45 Million ≈ $-504.87K |
CN¥3.23 Billion ≈ $472.29 Million |
-35.76pp |
| 2014-12-31 | 35.65% | CN¥1.02 Billion ≈ $149.99 Million |
CN¥2.87 Billion ≈ $420.69 Million |
+22.22pp |
| 2013-12-31 | 13.43% | CN¥330.00 Million ≈ $48.29 Million |
CN¥2.46 Billion ≈ $359.56 Million |
+13.48pp |
| 2012-12-31 | -0.05% | CN¥-977.11K ≈ $-142.98K |
CN¥1.95 Billion ≈ $284.80 Million |
-- |
| 2008-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥353.69 Million ≈ $51.76 Million |
-- |
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more